Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

• Main Authors: Jason Zhang (Author), Kinjal Sanghavi (Author), Jun Shen (Author), Xiaochen Zhao (Author), Yan Feng (Author), Paul Statkevich (Author), Jennifer Sheng (Author), Amit Roy (Author), Li Zhu (Author)
• Format: Book
• Published: Wiley, 2019-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Nivolumab is a fully human monoclonal antibody that inhibits programmed cell death‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal cancer, hepatocellular carcinoma, melanoma, non‐s...